NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell® Wearable Pain Relief Technology™.
The NeuroMetrix presentation is scheduled for Tuesday, December 6, 2016, at 8:00 a.m. Pacific Time (11:00 a.m. Eastern). A live audio webcast will be available on the investor relations section of the corporate website - http://www.NeuroMetrix.com/. This webcast will be archived after the live event.
Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell was recently named "Winner" in the Wearable Tech category at the SXSW Interactive Innovation Awards. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. For more information, visit www.ldmicro.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005172/en/Business Wire
Last updated on: 30/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.